Literature DB >> 3401503

Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II.

P Sié1, M Petitou, J C Lormeau, D Dupouy, B Boneu, J Choay.   

Abstract

The structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II (HC II) were investigated. A series of well characterized heparin derivatives were prepared and their activities were measured using human thrombin in the presence of an excess of purified human HC II and, for comparison, antithrombin III (AT III). The 50% inhibitory concentrations of each derivative were calculated and compared with those of unmodified heparin. Heparin activity was strongly dependent on molecular weight (Mr) in a manner grossly comparable for the two inhibitors. High-Mr fractions were the most active. Below 10 kDa, the activity dropped rapidly. A minimum size of 26 residues appeared to be required for HC II activation (against 16-18 for AT III). Below 5 kDa, a residual activity two orders of magnitude lower than that of high-Mr species remained with HC II (but not with AT III). Heparin was selectively desulfated or oversulfated in the O- and/or N-position. When an N-acetyl group was substituted for the original N-sulfate in the glucosamine and the derivative was oversulfated in the O-position, a strong activity with HC activities with both inhibitors decreased when the overall sulfate content (i.e., the charge density) was reduced, and vice-versa. Carboxyl-reduced heparin was also inactive but activity could be restored after O-sulfation. Our results thus suggest that, unlike the case of AT III, no functional group in heparin is critical for optimal thrombin inhibition by HC II. Sulfate and carboxylate are important in as much as they contribute to the global charge of the molecule.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401503     DOI: 10.1016/0304-4165(88)90111-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.

Authors:  B Bray; D A Lane; J M Freyssinet; G Pejler; U Lindahl
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

Review 2.  Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development.

Authors:  Daniel Radke; Wenkai Jia; Dhavan Sharma; Kemin Fena; Guifang Wang; Jeremy Goldman; Feng Zhao
Journal:  Adv Healthc Mater       Date:  2018-05-07       Impact factor: 9.933

Review 3.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

Review 4.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

5.  Low-molecular-weight heparin in the treatment of deep venous thrombosis.

Authors:  K E Hauer
Journal:  West J Med       Date:  1998-10

6.  Structure and contribution to the heparin cofactor II-mediated inhibition of thrombin of naturally oversulphated sequences of dermatan sulphate.

Authors:  G Mascellani; L Liverani; P Bianchini; B Parma; G Torri; A Bisio; M Guerrini; B Casu
Journal:  Biochem J       Date:  1993-12-15       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.